COUR Pharmaceuticals Secures $105 Million Series A
Chicago – January 30, 2024 – Cooley advised COUR Pharmaceuticals, a clinical-stage biotechnology company focused on the development of ﬁrst-in-class disease-modifying therapies designed to induce antigen-speciﬁc tolerance for immune-mediated diseases, on the close of its $105 million Series A financing, bringing its total raised to date to $130 million. Lawyers Winston Gu, Marc Recht, Christina Roupas, Yvan-Claude Pierre, Joyce Kim, Grant Page and Andrew Mettry led the Cooley team advising COUR.
The financing was co-led by Lumira Ventures and Alpha Wave Ventures, with participation from Roche Venture Fund, Pfizer (as part of the Pfizer Breakthrough Growth Initiative), Bristol Myers Squibb, Angelini Ventures and the JDRF T1D Fund. The proceeds will enable COUR to advance multiple wholly owned product candidates that leverage its immune tolerance platform, including phase 2a proof-of-concept clinical studies in myasthenia gravis and Type 1 diabetes, along with other pipeline opportunities.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has more than 1,300 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.